1-alpha-hydroxyvitamin-D5-HER-2 antibody conjugate
Latest Information Update: 23 Apr 2002
Price :
$50 *
At a glance
- Originator Nonindustrial source
- Class Drug conjugates; Immunoconjugates
- Mechanism of Action
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
Highest Development Phases
- No development reported Breast cancer
Most Recent Events
- 11 Aug 2000 Preclinical development for Breast cancer in USA (Unknown route)